Female condom technology: new products and regulatory issues

Area of Science:

• Public Health
• Medical Devices
• Reproductive Health

Background:

• Female condoms (FCs) are crucial barriers for preventing unplanned pregnancies and sexually transmitted infections (STIs), including HIV.
• The first FC received USFDA approval in 1993, with subsequent developments aiming to enhance cost-effectiveness and user acceptance.
• New FC designs vary significantly in materials and construction, presenting unique regulatory challenges.

Purpose of the Study:

• To review the current regulatory pathway for female condoms (FCs) in the US.
• To assess the progress in establishing international standards for FC quality.
• To provide an overview of available and developing FCs, including their regulatory approval status.

Main Methods:

• Review of existing regulatory frameworks for Class III medical devices, specifically FCs.
• Analysis of the development and implementation of international standards for FC quality assurance.
• Compilation and examination of data on current and emerging FC products and their market approval status.

Main Results:

• FCs face a more complex regulatory process than male condoms due to their classification as Class III medical devices by the USFDA.
• The absence of a unified international standard for verifying FC quality impedes the market entry of novel devices.
• Several new FCs are in development, but regulatory and standardization challenges have slowed their approval.

Conclusions:

• The regulatory pathway for FCs, combined with a lack of international standards, presents significant barriers to innovation and market access.
• Addressing these regulatory and standardization issues is critical for increasing the availability of diverse and improved female condom options.
• Further development and streamlined approval processes are needed to ensure wider access to FCs for reproductive and sexual health.